➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Boehringer Ingelheim
Johnson and Johnson
Baxter
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Narlaprevir


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Narlaprevir?

Narlaprevir is an investigational drug.

There have been 7 clinical trials for Narlaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on May 7th 2014.

The most common disease conditions in clinical trials are Hepatitis, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.

There are twenty-seven US patents protecting this investigational drug and two hundred and ninety-three international patents.

Recent Clinical Trials for Narlaprevir
TitleSponsorPhase
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1AlmedisPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1ChromSystemsLabPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1Scientific Center EFiSPhase 2

See all Narlaprevir clinical trials

Clinical Trial Summary for Narlaprevir

Top disease conditions for Narlaprevir
Top clinical trial sponsors for Narlaprevir

See all Narlaprevir clinical trials

US Patents for Narlaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Narlaprevir   Start Trial Pharmaceutical formulations and methods of treatment using the same Schering Corporation (Kenilworth, NJ)   Start Trial
Narlaprevir   Start Trial Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease Schering Corporation (Kenilworth, NJ)   Start Trial
Narlaprevir   Start Trial Administration of HCV protease inhibitors in combination with food to improve bioavailability Schering Corporation (Kenilworth, NJ)   Start Trial
Narlaprevir   Start Trial 2,3-substituted indole derivatives for treating viral infections Schering Corporation (Kenilworth, NJ)   Start Trial
Narlaprevir   Start Trial Genetic markers associated with interferon-alpha response Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Narlaprevir   Start Trial Substituted indole derivatives and methods of use thereof Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Narlaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Narlaprevir Argentina 055198 2025-06-02   Start Trial
Narlaprevir Australia 2006252553 2025-06-02   Start Trial
Narlaprevir Brazil PI0610737 2025-06-02   Start Trial
Narlaprevir Canada 2611155 2025-06-02   Start Trial
Narlaprevir China 101212970 2025-06-02   Start Trial
Narlaprevir European Patent Office 1919478 2025-06-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Johnson and Johnson
Medtronic
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.